A recent study suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise programs.
Findings released in a major health publication shows that while overweight people often shed substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing such medications need to be aware of the potential of rapid rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
That rate of recovery means a return to starting weight in about one and a half years.
Comparing Therapies
The study, which reviewed 37 of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with older methods.
Scientists emphasize that people who lose weight through dieting typically experience a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors suggest the mechanism of the jabs accounts for the amplified rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
Health authorities advise the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts say that, given the significant potential of relapse, the therapy should be considered long-term.
This view is supported by pharmaceutical companies, who say that the results "highlight the chronic nature of obesity," similar to managing diseases like hypertension.
User Accounts
Individuals who have discontinued the jabs describe a powerful return of cravings.
"It felt as if something flipping and you're instantly starving," described an individual.
This challenge is exacerbated if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is higher among women than males.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while these medications are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on combined behavioural support.
